Endpoints News November 21, 2025

Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna

Plus, news about Blue Lake, Bambusa, Inhibikase Therapeutics and Olema Oncology: 🛑 Sarepta terminates Elevidys trial with Hansa Biopharma’s imlifidase: The study was examining whether Hansa’s imlifidase, an IgG antibody-cleaving enzyme, could help reduce ...